Bionano Genomics (BNGO) Total Non-Current Liabilities (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Total Non-Current Liabilities data on file, last reported at $27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (changed N/A YoY), and the FY2025 full-year result was $29.2 million, down 29.39% from the prior year.
• Total Non-Current Liabilities slipped to $27.3 million in Q1 2026, from $29.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $107.4 million in Q4 2023 to a low of $27.3 million in Q1 2026.
• A 5-year average of $47.1 million and a median of $42.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 137.86% in 2023 and plunged 61.53% in 2024, its largest moves.
• Tracing BNGO's Total Non-Current Liabilities over 5 years: stood at $45.1 million in 2022, then jumped by 137.86% to $107.4 million in 2023, then sank by 61.53% to $41.3 million in 2024, then fell by 29.39% to $29.2 million in 2025, then dropped by 6.24% to $27.3 million in 2026.
• Business Quant data shows BNGO's Total Non-Current Liabilities at $27.3 million in Q1 2026, $29.2 million in Q4 2025, and $41.3 million in Q4 2024.